We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Flabby pharma

31 March 2006 By Robert Cyran

Take Pfizer the world s biggest drugs group runs its balance sheet like a biotech with uncertain prospects. With net cash, slowing growth and a stock that hasn t moved in eight years, Pfizer could easily buy back $50bn in stock.

This content is for Subscribers only

or
If you need assistance please email breakingviews.clientsupport@thomsonreuters.com
 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)

We need you to verify your email address to continue. Please check your email/junk folder for our verification request.

Click here to resend the verification email.